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Serological methods exist that allow differentiating between recent 
and long-standing infections in persons infected with HIV. During 
a pilot study in Berlin between 2005 and 2007 methodologies 
have been evaluated. In a cross-sectional study blood samples, 
demographic, laboratory, clinical and behavioural data based on 
a KABP survey were collected from patients with newly diagnosed 
HIV infections. The BED-CEIA was used to determine recency of 
infection. Recent HIV infections contributed 54% (CI [95%]: 45; 
64) in MSM and 16% (CI [95%]: 0; 39) in patients with other 
transmission risks (p=0.041). Proportions of recent infections were 
significantly higher in MSM ≤30 years (p=0.019). The mean age 
was 33.9 (median 34 years) in recent compared with 38.6 years 
(median: 38 years) in long-standing infections (p=0.011). High-risk 
behaviour indicated through very low condom use in recently HIV 
infected MSM could be identified. The results of the pilot study 
support expectations that the modified application of the method 
may contribute to improving HIV prevention efforts in Germany. On 
this basis the Robert Koch Institute implemented a countrywide HIV 
incidence study to complement HIV surveillance in early 2008. The 
study is funded by the German Ministry of Health. Data on recent 
HIV infections and current HIV transmission risks are collected. 
Design, methods and impact are described in detail. 
Background
In Germany newly diagnosed human immunodeficiency virus 
(HIV) infections reached a peak of 2,360 cases in 1993. The 
number of cases reported to the Robert Koch Institute (RKI), the 
institution responsible for the national surveillance of infectious 
diseases in Germany, dropped continuously in the second half of the 
1990s, reaching the lowest level so far in 2001 with 1,443 cases. 
However, since 2001 this trend has been reversed and annual case 
reports increased to more than 2,750 cases in 2007 [1; Figure 
1]. There are several possible explanations for these changes: an 
increase in HIV transmission (“true” incident infections); improved 
(earlier) case detection and reporting following the implementation 
of the “Protection against Infection Act” (Infektionsschutzgesetz 
- IfSG) in 2001; an increased number of HIV tests performed; 
changing attitudes towards HIV testing; and more widespread 
availability of testing facilities and better access to these facilities. 
The limited data available suggest that the increase in HIV cases is 
partly due to a rising willingness to test for HIV in groups with a high 
risk of transmission [2]. The higher number of HIV tests (ELISA and 
Western blot) performed in German laboratories when comparing the 
year 1999 to 2004 and the augmented use of HIV-NAT in primary 
HIV diagnosis additionally indicate changes regarding HIV testing 
[3].The rising number of cases reported between 1996 and 1997 
may reflect increased testing for HIV following the implementation 
of highly active antiretroviral treatment (HAART). Recently the 
upwards trend in syphilis cases reported in Germany was discussed 
as a possible cofactor for increased HIV transmission in men having 
sex with men (MSM) [1]. However, the implications of these trends 
have not yet been analysed systematically. 
The proportion of reported HIV cases without information on the 
underlying transmission risk decreased from 42% to 13% between 
1993 and 2007, primarily reflecting amendments concerning case 
reporting [1]. In the same period the proportion of cases in MSM 
increased from 48% to 65%, whilst the proportion of cases with 
intravenous drug use decreased from 18% to 6%. Heterosexual 
transmission was constant at around 15-20%; persons originating 
from high prevalence countries (HPCs) as transmission risk for HIV 
contributed 11% of the total in 1993 and in 2007, with a peak 
of 25% in 2002 [1,2].
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Standard reports of newly diagnosed HIV infections do not permit 
the differentiation between recently acquired (incident) and long-
standing (prevalent) infections, since routinely applied serological 
HIV tests (screening and confirmatory tests) do not provide such 
information. The diagnosis of an HIV infection can be delayed by 
up to several years and the time between infection and diagnosis 
may be a number of years and vary considerably, thus estimating 
incidence rates accurately and effectively is difficult. However, 
incidence estimates are fundamental to understanding the current 
dynamics of the HIV epidemic.
Several other methods have proved suitable for the identification 
of recent (incident) HIV infections in patients with newly diagnosed 
HIV infections. The concept of recent infections in HIV usually 
covers a period up to six months prior to the diagnosis depending 
on the diagnostic assay used [4-9]. Testing for recent HIV infections 
was implemented as an additional component (anonymous and 
unlinked) of the national HIV surveillance systems in France [10,11], 
Switzerland [12] and in 22 federal states of the United States of 
America [13] and was used in selected population groups at risk 
for HIV infection in the United Kingdom and South Africa [14,15]. 
Collection of additional data on knowledge, attitudes, behaviour and 
practices (KABP survey) concerning HIV from patients identified as 
recently infected with HIV permits analysis of risks and protective 
factors effective in HIV transmission. Subpopulations at increased 
risk for acquiring HIV and with limited access to diagnostic services 
can be identified by comparing KABP data between risk groups.
After encouraging results from a pilot study in Berlin, a 
nationwide study including, testing for recent HIV infections and 
a KABP survey was started in Germany in March 2008. The study 
aims to provide a better picture of the current dynamics and drivers 
of the HIV epidemic based on incidence estimates. The results are 
expected to help amend the national prevention strategies.
Pilot Study in Berlin 2005-2007
A pilot study conducted in Berlin from 2005 to 2007 assessed 
the feasibility of the methodologies described above and the impact 
of the results for future HIV surveillance in Germany. The design 
was cross-sectional with voluntary sampling after obtaining patients’ 
written informed consent. Sampling was anonymous and unlinked 
with no particular risk group being targeted. Exclusion criteria 
were clinical stage C HIV infection according to the US Centres 
for Diseases Control and Prevention (CDC) classification [16] and 
antiretroviral treatment. Clinicians in specialised private practices 
and clinic outpatient departments (OPD) collected venous blood 
and clinical data from adults aged 18 years or older with newly 
diagnosed HIV infections. Twenty of nearly 50 HIV-specialised 
facilities agreed to participate in the study. To determine a recent 
HIV infection the blood samples were tested using the BED-CEIA, 
one of the methods able to detect recent HIV infections serologically 
in patients with confirmed HIV diagnosis [17]. The BED-CEIA was 
established using a German HIV seroconverter sample panel with 
known time of seroconversion. Optimal cut-offs separating recent 
and long-standing samples in the reference panel were found with 
an optical density (ODn) of ≤0.8 for the BED-CEIA and duration of 
infection of 20 weeks [18]. KABP data with regards to HIV/AIDS 
were collected through patients’ questionnaires. Test results were 
not delivered to the patients. 
Results
Of 132 cases sampled, 114 were included in the study, 18 did 
not meet the eligibility criteria. 
The 132 cases represent 27% of all newly diagnosed HIV 
cases reported to the RKI from the Federal State of Berlin during 
the study period between November 2005 and February 2007 
(n=495). The total number of cases from Berlin accounted for 15% 
of all notifications from Germany. As far as data were available, 
all patients included had HIV-1 subtype B infections. Of the 114 
cases meeting the eligibility criteria for the study, 102 were MSM 
(89%) and 12 had other HIV transmission risks. 
Proportions of recent out of newly diagnosed HIV infections were 
found to be 54% in MSM (95% Confidence Interval (CI): 38-56) 
and 16% (95% CI: 32-0) in patients stating other risks. Proportions 
of recent infections were significantly higher in MSM ≤30 years 
(p=0.019), mean age was 33.9 (median 34 years) in patients with 
recent and 38.6 years (median: 38 years) in patients with long-
standing infections (p=0.011). Symptoms of acute seroconversion 
correlated significantly with recent HIV infections (p=0.009). Mean 
viral load (VL) was significantly higher in recent HIV infections 
compared with long-standing infections (1,608,801 copies/μl and 
141,951 copies/μl, respectively, p=0.009). A correlation was also 
found between recency of HIV infection and CD4 cell counts: counts 
>500/μml were indentified in recent HIV infections and counts 
≤200/μml in long-standing infections; however, this correlation 
was not statistically significant (p=0.08). 
Patients recruited for the pilot study showed a selection bias 
with samples from MSM being overrepresented (72% MSM in 
all cases reported from Berlin compared with 89% in the study 
sample). However, comparison of basic demographic variables in 
case reports of MSM from Berlin and MSM in the Berlin pilot study 
sample did not show statistically significant differences within 
the study period. High-risk behaviour indicated through very low 
condom use in recently HIV-infected MSM could be identified: 
>90% did not use condoms during sexual intercourse in the six 
months prior to HIV diagnosis and 19% stated that they did not use 
condoms despite being aware that their sexual partner had tested 
positive for HIV [19].
Conclusions
We were not able to produce incidence estimates since essential 
denominators are currently not available in Germany. Nevertheless, 
the results of the pilot study support expectations that the modified 
application of the method will contribute to amending and improving 
HIV prevention efforts in Germany. 
National HIV Incidence Surveillance Programme 2008 - 2010
Since November 2007 the RKI initiated a nationwide study 
funded by the German Ministry of Health (BMG) to collect data 
on recent HIV infections and current HIV transmission risks. The 
results are expected to complement the available data on HIV from 
the general surveillance by identifying subpopulations presently 
at increased risk for acquiring HIV infections and the risks most 
recently having an impact on HIV transmission in Germany.
Design and methods
To obtain the desired information a cross-sectional unlinked 
anonymous study, with a case control component will be conducted 
from 1 March 2008 to 28 February 2010. Samples and data are 
collected over this period through either laboratories or specialised 
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clinical centres. Information on screening patterns for all cases is 
gathered in both the laboratory and clinical study arm. As data from 
the two study arms cannot be linked, overlapping of sampling from 
patients in both study arms cannot be excluded.
Laboratory study arm
Collaborating Institutions
Newly diagnosed HIV cases in Germany are reported to the RKI 
by more than 200 laboratories. Only 36 labs, however, contribute 
significant numbers to the reporting of newly diagnosed HIV 
infections (significant defined as providing each at least 1% of 
the total number of cases reported nationally). These 36 labs are 
responsible for almost 70% of all reported newly diagnosed HIV 
cases in Germany, with the remaining approximately 170 labs 
reporting another 30%. All 36 laboratories reporting high numbers 
of HIV infections agreed to participate in the national HIV incidence 
study (exhaustive sampling). Thirty-five of 51 randomly selected 
laboratories with HIV case reporting on a smaller scale also agreed 
to participate (random sample). Thus, a total of countrywide 71 
laboratories will constitute the laboratory study arm.
Methods
Participating laboratories will collect plasma or serum samples 
from all newly diagnosed HIV cases during the study period. 
Samples are provided as “Dried Plasma Spots” (DPS) or “Dried 
Serum Spots” [20] and sent every month to the project group HIV 
Variability and Molecular Epidemiology at the RKI. All samples are 
tested for recency of HIV infection using the BED-CEIA. Clinical data 
are limited to information reported according to the national HIV 
surveillance regulations [21]. Data will allow to estimate recent HIV 
infections and incidence proportions by using basic demographic 
data and to analyse the risks to acquire an HIV infection. Data 
collected in this study arm are expected to be representative for 
Germany. The sample size is expected to include 1,600 cases 
annually representing around 60% of all new HIV diagnoses.
Clinical study arm
Collaborating Institutions
Over 80 clinical facilities specialised in HIV diagnosis and care 
from six regions in Germany will participate in the clinical study 
arm. The regions selected include those reporting the highest 
HIV case numbers nationally since 2001 (Figure 2) and they are 
characterised by a concentration of medical facilities specialised 
in HIV care compared with other regions. These facilities include 
private practitioners, clinic OPDs and counselling centres run by 
local health authorities or non-government organisations (NGO). 
Methods
In this study arm clinicians specialised in HIV diagnosis and care 
will recruit patients with newly diagnosed HIV infections (cases) 
and patients undergoing an HIV test with negative result (controls). 
Cases and controls will be matched by basic demographic variables 
and their risk of HIV transmission. HIV testing for cases and their 
respective controls has to be performed within a three month 
period. After obtaining written informed consent, blood samples 
are collected from case patients as DBS [22]. The samples are 
analysed for recency of HIV infection by BED-CEIA at the HIV 
Variability and Molecular Epidemiology project group of the Robert 
Koch Institute. Clinical and medical history data from case and 
control patients are collected through a physician’s questionnaire. 
KABP-data are collected from cases and controls by using a self-
administered patient’s questionnaire. The expected sample size is 
600 cases and controls annually. Analyses of the data will allow 
comparison between patients with recently acquired HIV infection 
and persons undergoing HIV tests with a negative test result in 
the same clinical institutions and in an identical time frame. The 
analyses aim at obtaining information on the current status of 
general knowledge about HIV/AIDS, on the behaviour and attitudes 
towards prevention of HIV transmission, and on the risks taken with 
regards to HIV transmission. 
Impact
The study offers an outstanding opportunity to identify recent 
HIV infections out of newly diagnosed cases and estimate HIV 
incidence. As a result of this a deeper insight into the transmission 
dynamics of the ongoing HIV epidemic in Germany will be available. 
To prevent further HIV infections, comparative analyses are aimed 
at identifying the risks for HIV transmission and the relevant 
behaviour and attitudes. However, the major limitations of our 
study are insufficient screening patterns that only reflect those 
patients requesting an HIV test. True incidence estimates will be 
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difficult to obtain as the denominators needed are not available in 
Germany. Despite these limitations the data are expected to have 
an impact on amending and improving national prevention efforts 
and strategies in Germany. Better knowledge of the factors driving 
the HIV epidemic and of the most recent dynamics of the epidemic 
revealing subgroups currently at increased risk of acquiring HIV will 
help to design targeted and prompt interventions.
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